Biomarker Guided Treatment in DLBCL

• Status: Recruiting
• Trial end date: 2023-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to investigate the strategy of biomarker guided treatment in diffuse large B cell lymphoma

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ruijin Hospital
• Treatments: Cyclophosphamide; Decitabine; Doxorubicin; Lenalidomide; Prednisone; Rituximab; Vincristine

Criteria

Inclusion Criteria:

• Pathologically confirmed diffuse large B-cell lymphoma, CD20 positive

• ECOG 0,1,2

• Life expectancy>6 months

• Informed consented

• IPI>1

Exclusion Criteria:

• Chemotherapy before

• Stem cell transplantation before

• History of malignancy except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix

• Uncontrollable cardio-cerebral vascular, coagulative, autoimmune, serious infectious disease

• Primary CNS lymphoma

• LVEF≤50%

• Lab at enrollment (Unless caused by lymphoma) Neutrophile<1.5*10^9/L Platelet<75*10^9/L ALT or AST >2*ULN,AKP or bilirubin >1.5*ULN Creatinine>1.5*ULN Other uncontrollable medical condition that may that may interfere the participation of the study Not able to comply to the protocol for mental or other unknown reasons Pregnant or lactation HIV infection If HbsAg positive, should check HBV DNA, DNA positive patients cannot be enrolled. If HBsAg negative but HBcAb positive (whatever HBsAb status), should check HBV DNA,DNA positive patients cannot be enrolled.